The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants

Sarah Dudley; Shawn Sen; Alison Hanson; Afif El Khuffash; Philip T. Levy

doi:10.1038/s41372-022-01450-1

The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants

Sarah Dudley, Shawn Sen, Alison Hanson, Afif El Khuffash, Philip T. Levy^*

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

Abstract

A patent ductus arteriosus (PDA) in infants born premature can present significant management challenges for neonatal providers. Quantifying a hemodynamically significant PDA (hsPDA) represents the first hurdle, however, identifying the best evidence-based approach amongst conservative, pharmacologic, and/or interventional management options has proven to be even more complicated. Within the conservative arm, furosemide to reduce pulmonary edema and improve lung function has spawned several discussions given the concerns for its upregulation of prostaglandin E₂ in the kidneys and conflicting outcomes data. There remains no consensus regarding furosemide use in hsPDAs.

Original language	English (US)
Pages (from-to)	1703-1707
Number of pages	5
Journal	Journal of Perinatology
Volume	42
Issue number	12
DOIs	https://doi.org/10.1038/s41372-022-01450-1
State	Published - Dec 2022

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Obstetrics and Gynecology

Access to Document

10.1038/s41372-022-01450-1

Cite this

@article{cc00dc88516247679feb5031595ed810,

title = "The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants",

abstract = "A patent ductus arteriosus (PDA) in infants born premature can present significant management challenges for neonatal providers. Quantifying a hemodynamically significant PDA (hsPDA) represents the first hurdle, however, identifying the best evidence-based approach amongst conservative, pharmacologic, and/or interventional management options has proven to be even more complicated. Within the conservative arm, furosemide to reduce pulmonary edema and improve lung function has spawned several discussions given the concerns for its upregulation of prostaglandin E2 in the kidneys and conflicting outcomes data. There remains no consensus regarding furosemide use in hsPDAs.",

author = "Sarah Dudley and Shawn Sen and Alison Hanson and {El Khuffash}, Afif and Levy, {Philip T.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Nature America, Inc.",

year = "2022",

month = dec,

doi = "10.1038/s41372-022-01450-1",

language = "English (US)",

volume = "42",

pages = "1703--1707",

journal = "Journal of Perinatology",

issn = "0743-8346",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants

AU - Dudley, Sarah

AU - Sen, Shawn

AU - Hanson, Alison

AU - El Khuffash, Afif

AU - Levy, Philip T.

PY - 2022/12

Y1 - 2022/12

N2 - A patent ductus arteriosus (PDA) in infants born premature can present significant management challenges for neonatal providers. Quantifying a hemodynamically significant PDA (hsPDA) represents the first hurdle, however, identifying the best evidence-based approach amongst conservative, pharmacologic, and/or interventional management options has proven to be even more complicated. Within the conservative arm, furosemide to reduce pulmonary edema and improve lung function has spawned several discussions given the concerns for its upregulation of prostaglandin E2 in the kidneys and conflicting outcomes data. There remains no consensus regarding furosemide use in hsPDAs.

AB - A patent ductus arteriosus (PDA) in infants born premature can present significant management challenges for neonatal providers. Quantifying a hemodynamically significant PDA (hsPDA) represents the first hurdle, however, identifying the best evidence-based approach amongst conservative, pharmacologic, and/or interventional management options has proven to be even more complicated. Within the conservative arm, furosemide to reduce pulmonary edema and improve lung function has spawned several discussions given the concerns for its upregulation of prostaglandin E2 in the kidneys and conflicting outcomes data. There remains no consensus regarding furosemide use in hsPDAs.

UR - http://www.scopus.com/inward/record.url?scp=85134319996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134319996&partnerID=8YFLogxK

U2 - 10.1038/s41372-022-01450-1

DO - 10.1038/s41372-022-01450-1

M3 - Article

C2 - 35840707

AN - SCOPUS:85134319996

SN - 0743-8346

VL - 42

SP - 1703

EP - 1707

JO - Journal of Perinatology

JF - Journal of Perinatology

IS - 12

ER -

The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this